Puma Biotechnology (PBYI) Change in Accured Expenses (2011 - 2026)

Puma Biotechnology (PBYI) has 16 years of Change in Accured Expenses data on file, last reported at -$11.7 million in Q1 2026.

• Quarterly Change in Accured Expenses fell 18.34% year-over-year to -$11.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.3 million (up 206.0% YoY) and the FY2025 annual result came in at $13.2 million, up 183.13% from the prior year.
• Change in Accured Expenses declined to -$11.7 million in Q1 2026, from $12.9 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $20.7 million in Q4 2022 to a low of -$30.9 million in Q1 2022.
• A 5-year average of -$3.2 million and a median of -$1.6 million in 2023 frame the typical range for Change in Accured Expenses.
• The widest YoY moves for Change in Accured Expenses: up 1283.49% in 2022, down 371.28% in 2022.
• Tracing PBYI's Change in Accured Expenses over 5 years: stood at $20.7 million in 2022, then tumbled by 45.26% to $11.3 million in 2023, then slumped by 221.48% to -$13.8 million in 2024, then soared by 193.54% to $12.9 million in 2025, then sank by 190.83% to -$11.7 million in 2026.
• The last three Change in Accured Expenses figures came in at -$11.7 million (Q1 2026), $12.9 million (Q4 2025), and $5.3 million (Q3 2025), per Business Quant data.